30 Participants NeededMy employer runs this trial

Brain-Computer Interface for ALS

CS
Overseen ByCognixion Study Team
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Cognixion
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.

As ALS progresses, speech is lost and many people come to rely on an eye-tracking speech generating device. Eye-tracking performance can decline as oculomotor control is affected, and some people reach a point where it no longer works reliably for them. The Cognixion ONE device adds a brain-computer interface input, which does not depend on eye movement, alongside an AI-assisted communication application.

Thirty adults with ALS who currently use a Tobii Dynavox or Smartbox eye-tracking device will take part. Each participant uses three communication options at home over a 12-week period: their own eye-tracking device, the Cognixion ONE device with a head-worn augmented-reality display, and the Cognixion ONE device with a screen-based display. For some sessions the option is assigned; for others the participant chooses.

The main measure is how much time participants voluntarily choose to spend using each option. That choice is treated as the clearest signal of which option genuinely works better for them. The study also measures communication speed and accuracy, usability, workload, quality of life, and caregiver burden.

The Cognixion ONE device is an investigational research device. It is not approved or cleared by the U.S. Food and Drug Administration for any medical use.

Who Is on the Research Team?

CU

Chris Ullrich, M.Sc.

Principal Investigator

Cognixion Corporation

Are You a Good Fit for This Trial?

This trial is for adults with ALS who currently use an eye-tracking speech device (like Tobii Dynavox or Smartbox) to communicate. Participants must be able to try new communication devices at home over a 12-week period.

Inclusion Criteria

I am 18 years old or older.
I can communicate yes or no using sounds or simple movements.
I have been diagnosed with ALS by a neurologist using accepted criteria.
See 5 more

Exclusion Criteria

I do not have cognitive or behavioral issues that would prevent me from joining the study.
I have a history of seizures triggered by light or currently have active seizures.
I have severe vision problems that cannot be corrected.
See 9 more

What Are the Treatments Tested in This Trial?

Interventions

  • Cognixion ONE AR-BCI configuration
  • Cognixion ONE screen-based BCI configuration

Trial Overview

The study compares three ways for people with ALS to communicate: their usual eye-tracking device, the Cognixion ONE brain-computer interface (BCI) headset, and a screen-based version of Cognixion ONE. Each participant tries all options at home.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Active Control

Group I: Cognixion ONE - screen-based BCI configurationExperimental Treatment1 Intervention
Group II: Cognixion ONE - AR-BCI configurationExperimental Treatment1 Intervention
Group III: Existing eye-gaze speech generating deviceActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cognixion

Lead Sponsor

Trials
1
Recruited
10+

National Institute on Deafness and Other Communication Disorders (NIDCD)

Collaborator

Trials
377
Recruited
190,000+